Nogo-B promotes the epithelial-mesenchymal transition in HeLa cervical cancer cells via Fibulin-5 Corrigendum in /10.3892/or.2022.8311

Xiao,Wei; Zhou,Shumin; Xu,Hua; Li,Heng; He,Guoqing; Liu,Yingle; Qi,Yipeng

doi:10.3892/or.2012.2069

Nogo-B promotes the epithelial-mesenchymal transition in HeLa cervical cancer cells via Fibulin-5

Corrigendum in: /10.3892/or.2022.8311

Authors:
- Wei Xiao
- Shumin Zhou
- Hua Xu
- Heng Li
- Guoqing He
- Yingle Liu
- Yipeng Qi
View Affiliations

Affiliations: State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Hubei, Wuhan, P.R. China, Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, Wuhan, P.R. China
Published online on: October 4, 2012 https://doi.org/10.3892/or.2012.2069
Pages: 109-116

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cervical cancer is a common malignancy in women worldwide, and the occurrence of invasion and metastasis is the major cause for most cancer-related deaths. Epithelial-mesenchymal transition (EMT) has been implicated in the metastasis of primary tumors and provides molecular mechanisms for cervical cancer metastasis. We previously reported that Nogo-B mediates cell motility by binding Fibulin-5. Herein, we show that the increased expression of Nogo-B is correlated with the degree of cervical cancer metastasis. In HeLa cervical cancer cells, overexpression of Nogo-B induces the EMT and promotes cell migration and invasion, while inhibiting cell adhesion. Furthermore, we found that Nogo-B accumulates and co-localizes with Fibulin-5 in pseudopods, and the downstream effects of overexpression of Nogo-B on cell motility could be partially abolished by RNA interference against Fibulin-5. These results suggest that Nogo-B functions as an inducer of cervical cancer metastasis and that this effect is mediated, at least in part, through Fibulin-5.

View Figures

View References

1	zur Hausen H: Human papillomaviruses in the pathogenesis of anogenital cancer. Virology. 184:9–13. 1991.PubMed/NCBI
2	Lee MY, Chou CY, Tang MJ and Shen MR: Epithelial-mesenchymal transition in cervical cancer: correlation with tumor progression, epidermal growth factor receptor overexpression, and snail up-regulation. Clin Cancer Res. 14:4743–4750. 2008. View Article : Google Scholar
3	Hay ED: An overview of epithelio-mesenchymal transformation. Acta Anat. 154:8–20. 1995. View Article : Google Scholar : PubMed/NCBI
4	Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002. View Article : Google Scholar : PubMed/NCBI
5	Yang J and Weinberg RA: Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 14:818–829. 2008. View Article : Google Scholar : PubMed/NCBI
6	Oertle T, Merkler D and Schwab ME: Do cancer cells die because of Nogo-B? Oncogene. 22:1390–1399. 2003. View Article : Google Scholar : PubMed/NCBI
7	Su Z, Cao L, Zhu Y, et al: Nogo enhances the adhesion of olfactory ensheathing cells and inhibits their migration. J Cell Sci. 120:1877–1887. 2007. View Article : Google Scholar : PubMed/NCBI
8	Qi B, Qi Y, Watari A, et al: Pro-apoptotic ASY/Nogo-B protein associates with ASYIP. J Cell Physiol. 196:312–318. 2003. View Article : Google Scholar : PubMed/NCBI
9	Kuang E, Wan Q, Li X, Xu H, Zou T and Qi Y: ER stress triggers apoptosis induced by Nogo-B/ASY overexpression. Exp Cell Res. 312:1983–1988. 2006. View Article : Google Scholar : PubMed/NCBI
10	Liao H, Duka T, Teng FY, et al: Nogo-66 and myelin-associated glycoprotein (MAG) inhibit the adhesion and migration of Nogo-66 receptor expressing human glioma cells. J Neurochem. 90:1156–1162. 2004. View Article : Google Scholar : PubMed/NCBI
11	Miao RQ, Gao Y, Harrison KD, et al: Identification of a receptor necessary for Nogo-B stimulated chemotaxis and morphogenesis of endothelial cells. Proc Natl Acad Sci USA. 103:10997–11002. 2006. View Article : Google Scholar : PubMed/NCBI
12	Albig AR and Schiemann WP: Fibulin-5 function during tumorigenesis. Future Oncol. 1:23–35. 2005. View Article : Google Scholar
13	Nakamura T, Ruiz-Lozano P, Lindner V, et al: DANCE, a novel secreted RGD protein expressed in developing, atherosclerotic, and balloon-injured arteries. J Biol Chem. 274:22476–22483. 1999. View Article : Google Scholar : PubMed/NCBI
14	Nakamura T, Lozano PR, Ikeda Y, et al: Fibulin-5/DANCE is essential for elastogenesis in vivo. Nature. 415:171–175. 2002. View Article : Google Scholar : PubMed/NCBI
15	Albig AR, Neil JR and Schiemann WP: Fibulins 3 and 5 antagonize tumor angiogenesis in vivo. Cancer Res. 66:2621–2629. 2006. View Article : Google Scholar : PubMed/NCBI
16	Zhou S, Xiao W, Wan Q, et al: Nogo-B mediates HeLa cell adhesion and motility through binding of Fibulin-5. Biochem Biophys Res Commun. 398:247–253. 2010. View Article : Google Scholar : PubMed/NCBI
17	Matsukura T and Sugase M: Pitfalls in the epidemiologic classification of human papillomavirus types associated with cervical cancer using polymerase chain reaction: driver and passenger. Int J Gynecol Cancer. 18:1042–1050. 2008. View Article : Google Scholar
18	Munoz N, Bosch FX, de Sanjose S, et al: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 348:518–527. 2003. View Article : Google Scholar : PubMed/NCBI
19	zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2:342–350. 2002.PubMed/NCBI
20	Care A, Catalucci D, Felicetti F, et al: MicroRNA-133 controls cardiac hypertrophy. Nat Med. 13:613–618. 2007. View Article : Google Scholar : PubMed/NCBI
21	Liang X: EMT: new signals from the invasive front. Oral Oncol. 47:686–687. 2011. View Article : Google Scholar : PubMed/NCBI
22	Christofori G: New signals from the invasive front. Nature. 441:444–450. 2006. View Article : Google Scholar : PubMed/NCBI
23	Huber MA, Kraut N and Beug H: Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol. 17:548–558. 2005. View Article : Google Scholar : PubMed/NCBI
24	Peinado H, Olmeda D and Cano A: Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer. 7:415–428. 2007. View Article : Google Scholar : PubMed/NCBI
25	Christofori G and Semb H: The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem Sci. 24:73–76. 1999. View Article : Google Scholar : PubMed/NCBI
26	Miettinen PJ, Ebner R, Lopez AR and Derynck R: TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J Cell Biol. 127:2021–2036. 1994. View Article : Google Scholar : PubMed/NCBI
27	Zavadil J and Bottinger EP: TGF-beta and epithelial-to-mesenchymal transitions. Oncogene. 24:5764–5774. 2005. View Article : Google Scholar : PubMed/NCBI
28	Li Q, Qi B, Oka K, et al: Link of a new type of apoptosis-inducing gene ASY/Nogo-B to human cancer. Oncogene. 20:3929–3936. 2001. View Article : Google Scholar : PubMed/NCBI
29	Acevedo L, Yu J, Erdjument-Bromage H, et al: A new role for Nogo as a regulator of vascular remodeling. Nat Med. 10:382–388. 2004. View Article : Google Scholar : PubMed/NCBI
30	Van Haastert PJ: How cells use pseudopods for persistent movement and navigation. Sci Signal. 4:62011.PubMed/NCBI
31	Lee YH, Albig AR, Regner M, Schiemann BJ and Schiemann WP: Fibulin-5 initiates epithelial-mesenchymal transition (EMT) and enhances EMT induced by TGF-beta in mammary epithelial cells via a MMP-dependent mechanism. Carcinogenesis. 29:2243–2251. 2008. View Article : Google Scholar : PubMed/NCBI